Stay updated on Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial
Sign up to get notified when there's something new on the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page.

Latest updates to the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedThe expected modernization date for the ClinicalTrials.gov data ingest has been updated from June 2025 to July 2025.SummaryDifference0.7%
- Check18 days agoChange DetectedThe web page has been updated from version 2.16.2 to version 2.16.3.SummaryDifference0.1%
- Check25 days agoChange DetectedThe web page has been updated from version 2.16.1 to version 2.16.2.SummaryDifference0.1%
- Check32 days agoChange DetectedThe web page has been updated to reflect the upcoming modernization of the ClinicalTrials.gov data ingest scheduled for June 2025, along with an invitation for API users to provide input. Additionally, the revision number has been updated from v2.16.0 to v2.16.1.SummaryDifference1%
- Check61 days agoChange DetectedThe web page has been updated from version 2.15.0 to version 2.15.2.SummaryDifference0.1%
- Check75 days agoChange DetectedThe webpage has been updated to reflect a new version of the study on Daratumumab and Dexamethasone for relapsed/refractory multiple myeloma, with changes in the principal investigator and collaborators. Key details about the study's purpose and methodology have been removed, which may impact the understanding of the study's scope.SummaryDifference42%
Stay in the know with updates to Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Daratumumab in Renal-Impaired Myeloma: Efficacy Clinical Trial page.